Abstract: An interface device for provisioning Internet Protocol (IP) communications to be established for base station equipment that employ proprietary device specific protocols. A fixed station interface (FSI) translates between a V.24 High-Level-Data-Link Control (HDLC) protocols used for external data connections on base station equipment to a Voice-Over-Internet-Protocol (VOIP) open-standard protocol. Upon being deployed in First Responder communications networks (that use legacy base station equipment), the FSI provisions for the retention of existing installed base station equipment while providing a low cost solution to support VOIP communications interconnectivity and reliability, thereby enhancing the effectiveness and safety of the First Responder systems.

Abstract: A method is provided herein to increase an immune response to an antigen. The method includes administering an agent that inhibits extracellular adenosine or inhibits adenosine receptors. Also disclosed are methods to increase the efficacy of a vaccine and to increase an immune response to a tumor antigen or immune cell-mediated tumor destruction.

Abstract: A process for detecting Neisseria meningitidis nucleic acid in a sample is provided including producing an amplification product by amplifying Neisseria meningitidis nucleotide sequence of the sodC gene or mRNA using a forward primer of SEQ ID NO: 1, and a reverse primer of SEQ ID NO: 2, and detecting the amplification product to detect Neisseria meningitidis in the sample. Also provided are reagents and methods for detecting and distinguishing Neisseria meningitidis from other infectious agents. A kit is provided for detecting and quantifying Neisseria meningitidis in a sample.

Abstract: The invention provides modified vaccinia Ankara (MVA), a replication-deficient strain of vaccinia virus, expressing human immunodeficiency virus (HIV) env, gag, and pol genes.

Abstract: This application provides photoinduced electron transfer (PET) nucleic acid molecules that can be used detect and amplify nucleic acid molecules, such as target nucleic acid molecules. These PET tags can be attached to the 5?-end of a target sequence-specific primer, thereby generating a PET primer. In particular examples, a PET tag includes a 5?-labeled nucleotide that can be quenched by at least two consecutive Gs within the tag sequence, and is unquenched when the PET tag hybridizes with its complementary nucleic acid molecule. Also disclosed are methods of using PET primers in nucleic acid amplification, such as real-time PCR.

Abstract: Methods and compositions for the treatment of prostate associated disorders are disclosed.

Abstract: Methods and compositions for the treatment of prostate associated disorders are disclosed.

Abstract: Methods and compositions for the treatment of prostate associated disorders are disclosed.

Abstract: Methods and compositions for the treatment of prostate associated disorders are disclosed.

Abstract: A reticle for a projectile weapon aiming apparatus including a plurality of aiming marks, the plurality of aiming marks include a first mark positioned at the center of the reticle and at least one additional mark spaced below the first mark along a vertical center axis of the reticle, wherein adjacent marks of the first mark and the at least one additional mark are spaced apart by predetermined distances. First and second horizontal stripes are provided on each side of the plurality of aiming marks respectively, the first and second horizontal stripes offset relative to the vertical center axis with a gap provided therebetween and extending towards the perimeter of the reticle, the first and second horizontal stripes spaced a predetermined distance from a bottom of the reticle measured along the vertical center axis.

Abstract: Disclosed herein are isolated human monoclonal antibodies that specifically bind human CD22 with a dissociation constant (Kd) of 25 nM or less. Nucleic acids encoding these antibodies, expression vectors including these nucleic acid molecules, and isolated host cells that express the nucleic acid molecules are also disclosed. The antibodies can be used to detect human CD22 in a sample. In some cases, CD22 is soluble CD22. Methods of diagnosing a B-cell malignancy, or confirming a B-cell malignancy diagnosis, are disclosed herein that utilize these antibodies. Methods of treating a subject with a B-cell malignancy are also disclosed.

Abstract: This application is directed to a firearm that is functional, but is not fully functional as it is incapable of discharging ammunition, e.g., causing ammunition to ignite and discharge a bullet. Related methods, techniques, and approaches are also discussed. In embodiments, the firearm is functional, but not fully functional and it is impractical and/or irreversible to alter the firearm to make it fully functional through replacement of interchangeable parts that correspond to that particular firearm model. In embodiments, the firearm is also identifiable as being less than fully functional, e.g., it is incapable of discharging ammunition.

Abstract: Mobile collection and vetting of user supplied information is described. The systems, techniques, devices, methods, and approaches described herein can be used to obtain, validate, and vet information, such as customs information, in a mobile environment. In embodiments, methods comprise receiving information input via a mobile device. The information is encapsulated by an intermediate to escort the information through a firewall to the database. In response to vetting the information to determine if it meets one or more criteria, the method involves creating a record associated with a unique identifier, information that bio-identifies a user, or an indication of a determination that results from the vetting. In this embodiment, the method includes generating an electronic receipt for communication to the mobile device, the electronic receipt including the unique identifier.

Abstract: Described herein is a method of identifying a monoclonal antibody (or antigen-binding fragment thereof) that specifically binds a plurality of lyssaviruses for use in post-exposure rabies prophylaxis or in the treatment of clinical rabies. The method includes using a naïve antibody phage display library to screen for phage clones that bind whole recombinant rabies virus or cells expressing glycoprotein from multiple lyssaviruses (such as RABV, MOKV and WCBV) and/or specifically bind recombinant glycoprotein from different lyssaviruses.

Abstract: Provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-? therapy, by detecting the level of microRNA-26 expression in a sample obtained from the patient.

Abstract: Substantially purified salivary Lu. longipalpis polypeptides, and polynucleotides encoding these polypeptides are disclosed. Vectors and host cells including the Lu. longipalpis polynucleotides are also disclosed. In one embodiment, a method is disclosed for inducing an immune response to sand fly saliva. In other embodiments, methods for treating, diagnosing, or preventing Leishmaniasis are disclosed.

Abstract: Disclosed herein are point mutations in the LMNA gene that cause HGPS. These mutations activate a cryptic splice site within the LMNA gene, which leads to deletion of part of exon 11 and generation of a mutant Lamin A protein product that is 50 amino acids shorter than the normal protein. In addition to the novel Lamin A variant protein and nucleic acids encoding this variant, methods of using these molecules in detecting biological conditions associated with a LMNA mutation in a subject (e.g., HGPS, arteriosclerosis, and other age-related diseases), methods of treating such conditions, methods of selecting treatments, methods of screening for compounds that influence Lamin A activity, and methods of influencing the expression of LMNA or LMNA variants are also described.

Abstract: Vitronectin is found to be a biomarker of progression from dengue fever to dengue hemorrhagic fever according to the present invention. Assay of vitronectin in biological samples of dengue virus infected subjects aids in prognosis, diagnosis and treatment of the disease, particularly in prediction of progression from dengue fever to severe dengue i.e. dengue hemorrhagic fever/dengue shock syndrome.

Abstract: Derivatives of a novel antiproliferative factor comprising a glycopeptide is disclosed. In specific embodiments, the novel antiproliferative factor is associated with the bladder. Compositions, diagnostic kits and reagents, and methods of using the compounds for identifying and/or treating interstitial cystitis and cancer are disclosed. In particular embodiments, the glycopeptide comprises D-proline.

Abstract: A method of isolating non-expanded post-natal multilineage-inducible cells has the steps of obtaining a biological sample from an animal; isolating bone marrow from the biological sample, isolating total nuclear cells (TNCs) obtained from the bone marrow, incubating the total nuclear cells in the presence of an antibody or a cell adhesion substrate, separating the cells to isolate non-expanded post-natal multilineage-inducible cells and isolating the non-expanded post-natal multilineage-inducible cells in the absence of expansion.